Development of an intranasal vaccine for SARS-CoV-2

Development of an intranasal vaccine for SARS-CoV-2

Show other versions (1)
Saved in:
Bibliographic Details
Other Authors: Roberts, Scot (Speaker)
Format: Electronic Audio
Language:English
Published: London : Henry Stewart Talks, 2020.
Series:Henry Stewart talks. Biomedical & life sciences collection. Interviews on Covid-19.
Subjects:
Adenoviruses.
Coronavirus infections > Immunological aspects.
COVID-19 (Disease) > Vaccination.
Transdermal medication.
Vaccines > Development.
Viral vaccines.
Adenoviridae.
Administration, Intranasal.
Betacoronavirus > drug effects.
Coronavirus Infections.
COVID-19 Vaccines.
COVID-19 > immunology.
COVID-19 > prevention & control.
Drug Development > methods.
Genetic Vectors.
SARS-CoV-2.
Vaccines, DNA.
Online Access:https://hstalks.com/bs/4271/
Series
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000nim a2200000 a 4500
001 HST8166
003 UkLoHST
006 m o h
007 cr nna||||||||
007 sr |mnnnnnzne|
008 200504s2020 enk|||||o||h||||||||eng d
028 5 0 |a 8166  |b Henry Stewart Talks 
035 |a (UkLoHST)4271 
040 |a UkLoHST  |b eng  |c UkLoHST 
100 1 |a Roberts, Scot,  |u (CSO, Altimmune, USA)  |4 spk  |9 89703 
245 1 0 |a Development of an intranasal vaccine for SARS-CoV-2  |h [electronic resource] /  |c Scot Roberts. 
260 |a London :  |b Henry Stewart Talks,  |c 2020. 
300 |a 1 online resource (1 streaming audio file (15 min.)). 
490 1 |a Interviews on Covid-19,  |x 2056-452X 
500 |a Audio interview. 
500 |a Title from title frames. 
505 0 |a Contents: General mechanism of action of DNA vaccines -- Adenoviral vectors for DNA delivery to host cells -- Advantages and limitations of intranasal vaccines -- Cellular, mucosal and antibody immunity in the context of SARS-2 -- Stability of AdCOVID at room temperature -- Earliest possible approval of AdCOVID -- How far and how fast can this vaccine then be deployed? 
506 |a Access restricted to subscribers. 
538 |a Mode of access: World Wide Web. 
650 0 |a Adenoviruses.  |9 89704 
650 0 |a Coronavirus infections  |x Immunological aspects.  |9 89705 
650 0 |a COVID-19 (Disease)  |x Vaccination.  |9 89706 
650 0 |a Transdermal medication.  |9 89707 
650 0 |a Vaccines  |x Development.  |9 89708 
650 0 |a Viral vaccines.  |9 89709 
650 2 |a Adenoviridae.  |9 89710 
650 2 |a Administration, Intranasal.  |9 89711 
650 2 |a Betacoronavirus  |x drug effects.  |9 89712 
650 2 |a Coronavirus Infections.  |9 89713 
650 2 |a COVID-19 Vaccines.  |9 89714 
650 2 |a COVID-19  |x immunology.  |9 89715 
650 2 |a COVID-19  |x prevention & control.  |9 89716 
650 2 |a Drug Development  |x methods.  |9 89717 
650 2 |a Genetic Vectors.  |9 89718 
650 2 |a SARS-CoV-2.  |9 89719 
650 2 |a Vaccines, DNA.  |9 89720 
830 0 |a Henry Stewart talks.  |p Biomedical & life sciences collection.  |p Interviews on Covid-19.  |9 89721 
856 4 0 |u https://hstalks.com/bs/4271/ 
856 4 2 |u https://hstalks.com/bs/p/1060/  |3 Series 
999 |c 214058  |d 214057 

Similar Items